Real-world Effectiveness of Combination Therapy in Asthma
Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
This study will evaluate and compare the effectiveness of asthma management in patients with
evidence of persistent asthma following a switch in asthma therapy to combination inhaled
glucocorticosteroid (ICS) / long-acting bronchodilator (LABA) therapy as either:
fixed-combination fluticasone propionate / salmeterol (FP/SAL; Seretide®) via pressurised
metered-dose inhaler (pMDI) or dry-powder inhaler (DPI) plus as-needed (prn) reliever therapy
(salbutamol as DPI, BAI or pMDI), or fixed-combination budesonide / formoterol (BUD/FOR;
Symbicort®) via DPI plus prn reliever therapy (salbutamol as DPI, BAI or pMDI or bricanyl as
DPI). The final analysis plan will define exact comparators and age groups to be studied
after reviewing baseline data.
Details
Lead Sponsor:
Research in Real-Life Ltd
Collaborator:
Mundipharma Research Limited
Treatments:
Budesonide Budesonide, Formoterol Fumarate Drug Combination Fluticasone Fluticasone Propionate, Salmeterol Xinafoate Drug Combination Fluticasone-Salmeterol Drug Combination Formoterol Fumarate Salmeterol Xinafoate Xhance